- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Scott Cormack, Oncogenex Pharmaceuticals
I began my career with an interest in medicine and pharmaceutical sciences.
Scott Cormack
President and CEO, OncoGenex Pharmaceuticals
I began my career with an interest in medicine and pharmaceutical sciences. In considering going into post-secondary education, I was introduced to a small biotech company pursuing immune modulation. I spoke with the company and was offered a position. The rest, as they say, is history.
Later, I cofounded OncoGenex with Martin Gleave. Since then, I've led OncoGenex through significant corporate milestones, including serial rounds of private financing, and taken the corporation from preclinical through completion of multiple Phase II clinical trials.
I believe in pursuing novel therapeutics to materially change disease management. OncoGenex's product pipeline is comprised of a majority of product candidates designed to inhibit novel targets. The company's randomized Phase II data in prostate cancer, which showed a 40 percent reduction in the rate of death compared to the gold standard therapy, demonstrates the success of this approach.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
